News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
20 April 2026

Dangote scales up amid energy market turmoil

Afreximbank has signed on fresh financing for Nigeria’s oil & gas industry at a moment of crisis for the global energy business. The conflict in the Gulf has further...

Perspective
24 April 2026

Jabiru-1: Who’s out of orbit?

The financial fallout from NewSat's failed Jabiru-1 satellite project financing could be stratospheric. Investors are claiming $1 billion or more in damages from banks as part...